Efficacy and safety of nab-paclitaxel in metastatic gastric cancer: a meta-analysis

mygutbraincenter

Aug 22

1 min read

Background

Nab-paclitaxel is formulated to address several limitations of paclitaxel.

Methods

A systematic review was done of several databases and a meta-analysis with a random-effects model was conducted to assess the efficacy and safety of nab-paclitaxel in metastatic gastric cancer (MGC).

Results

Included studies revealed that nab-paclitaxel provides a 30.4% overall response rate and 65.7% disease control rate in MGC patients. The overall survival was 9.65 months and progression-free survival was 4.48 months, associated with the treatment line and regimen. The highest incidence of grade 3 and higher treatment-related adverse events was for neutropenia (29.9%).

Conclusion

Nab-paclitaxel provides better disease response and longer survival with manageable side effects in MGC compared with paclitaxel.

Link to Paper >>

Recent Posts

See All

Stabler Sign Secondary to Postoperative Breast Hematoma: CT Evidence of Extraperitoneal Blood Tracking.

Chuah YY, Lee YY, Tzeng WS, Shiue YL Inguinal ecchymosis, known as Stabler sign, is classically associated with retroperitoneal hemorrhage. However, imaging confirmation of the underlying mechanism is

Future Global Outlook in Gastrointestinal and Liver Disorders: Consensus and Perspectives from the Leaders of Member Societies of the World Gastroenterology Organization.

Tagiling N, Simadibrata DM, Makharia GK, Sadgehi A, Moreira L, Leung WK, Kaplan GG, Leddin D, Metz G, Barkun AN, Lee YY Background And Aims Gastrointestinal (GI) and liver diseases are common and rema

Prevalence and Impact of Disorders of Gut-Brain Interaction in Indonesia: An Analysis from the Rome Foundation Global Epidemiology Study.

Simadibrata DM, Utari AP, Andarini L, Wijaya J, Hasanah NH, Cheng KY, Palsson OS, Sperber AD, Bangdiwala SI, Lee YY, Syam AF Background And Aims Disorders of gut-brain interaction (DGBI) significantly